BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

...lead the center.Kidney-on-a-chip model for real-time cellular metabolism measurementsResearchers from Tissue Dynamics Ltd. and The Hebrew University of Jerusalem...
BioCentury | Aug 2, 2019
Distillery Therapeutics

Gut microbe to reduce ALS severity

...Rehovat, Israel; German Cancer Research Center (DKFZ), Heidelberg, Germany e-mail: e.elinav@dkfzheidelberg.de Sandi Wong German Cancer Research Center (DKFZ) Hebrew University of Jerusalem Weizmann...
BioCentury | Jul 2, 2019
Preclinical News

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

...for cell type-specific synthetic promoters Timothy Lu and colleagues at Massachusetts Institute of Technology and Hebrew University of Jerusalem...
...drunk-like behaviors. Targets: CCR5 (CD195) - CC chemokine receptor 5; HTT - Huntingtin Sandi Wong, Staff Writer Hebrew University of Jerusalem Massachusetts...
BioCentury | Mar 25, 2019
Distillery Therapeutics

Two promoters of FMR1 expression to treat Fragile X syndrome

...et al. Cell Rep. ; published online Mar. 5, 2019 doi:10.1016/j.celrep.2019.02.026 CONTACT: Nissim Benvenisty, The Hebrew University of Jerusalem...
...nissimb@mail.huji.ac.il CONTACT: Tamir Ben-Hur, Hadassah University Medical Center, Jerusalem, Israel email: tamir@hadassah.org.il Claire Quang Hadassah University Medical Center Hebrew University of Jerusalem Fragile...
BioCentury | Oct 19, 2018
Preclinical News

Study uncovers large batch effects in TCGA exome sequencing data

...and harmonized protocol components including sequencing instruments and bioinformatics tools. In the article published Wednesday, Hebrew University of Jerusalem...
...closer to the truth," said Wheeler. Karen Tkach Tuzman Baylor College of Medicine Broad Institute of MIT and Harvard Hebrew University of Jerusalem Washington...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...FAM101A) Plasma levels of unmethylated RFLNA cell-free DNA (cfDNA) could help diagnose MI or sepsis. Hebrew University of Jerusalem...
BioCentury | May 31, 2018
Translation in Brief

Myocardial marker

...A group at the Hebrew University of Jerusalem has developed a non-invasive method to detect circulating cell-free DNA from...
...of human cardiomyocyte death using methylation patterns of circulating DNA.” Nature Communications (2018) Chris Lieu, Staff Writer Hebrew University of Jerusalem Refilin...
BioCentury | May 25, 2018
Preclinical News

Activating astrocytes to enhance memory

...In a paper published in Cell , researchers at The Hebrew University of Jerusalem showed that activating astrocytes in...
...neural network development and investigating whether astrocyte modulation could be translated into cognitive augmentation therapies. Sandi Wong Hebrew University of Jerusalem...
BioCentury | May 23, 2018
Distillery Techniques

Biomarkers

...Dor, Hebrew University of Jerusalem, Jerusalem, Israel email: yuvald@ekmd.huji.ac.il CONTACT: Giora Landesberg, same affiliation as above email: giora.lan@mail.huji.ac.il Chris Lieu Hebrew University of Jerusalem Refilin...
BioCentury | Dec 8, 2017
Company News

Therapix gains rights to synthetic cannabinoids from Hebrew University

...rights to IP for two synthetic cannabinoid compounds from Yissum Research Development Company Ltd., the Hebrew University of Jerusalem's...
...disorders. Hebrew University of Jerusalem, Jerusalem, Israel Therapix Biosciences Ltd. (Tel Aviv:TRPX; NASDAQ:TRPX), Tel Aviv, Israel Business: Neurology Jennie Walters Hebrew University of Jerusalem Therapix...
Items per page:
1 - 10 of 87
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

...lead the center.Kidney-on-a-chip model for real-time cellular metabolism measurementsResearchers from Tissue Dynamics Ltd. and The Hebrew University of Jerusalem...
BioCentury | Aug 2, 2019
Distillery Therapeutics

Gut microbe to reduce ALS severity

...Rehovat, Israel; German Cancer Research Center (DKFZ), Heidelberg, Germany e-mail: e.elinav@dkfzheidelberg.de Sandi Wong German Cancer Research Center (DKFZ) Hebrew University of Jerusalem Weizmann...
BioCentury | Jul 2, 2019
Preclinical News

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

...for cell type-specific synthetic promoters Timothy Lu and colleagues at Massachusetts Institute of Technology and Hebrew University of Jerusalem...
...drunk-like behaviors. Targets: CCR5 (CD195) - CC chemokine receptor 5; HTT - Huntingtin Sandi Wong, Staff Writer Hebrew University of Jerusalem Massachusetts...
BioCentury | Mar 25, 2019
Distillery Therapeutics

Two promoters of FMR1 expression to treat Fragile X syndrome

...et al. Cell Rep. ; published online Mar. 5, 2019 doi:10.1016/j.celrep.2019.02.026 CONTACT: Nissim Benvenisty, The Hebrew University of Jerusalem...
...nissimb@mail.huji.ac.il CONTACT: Tamir Ben-Hur, Hadassah University Medical Center, Jerusalem, Israel email: tamir@hadassah.org.il Claire Quang Hadassah University Medical Center Hebrew University of Jerusalem Fragile...
BioCentury | Oct 19, 2018
Preclinical News

Study uncovers large batch effects in TCGA exome sequencing data

...and harmonized protocol components including sequencing instruments and bioinformatics tools. In the article published Wednesday, Hebrew University of Jerusalem...
...closer to the truth," said Wheeler. Karen Tkach Tuzman Baylor College of Medicine Broad Institute of MIT and Harvard Hebrew University of Jerusalem Washington...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...FAM101A) Plasma levels of unmethylated RFLNA cell-free DNA (cfDNA) could help diagnose MI or sepsis. Hebrew University of Jerusalem...
BioCentury | May 31, 2018
Translation in Brief

Myocardial marker

...A group at the Hebrew University of Jerusalem has developed a non-invasive method to detect circulating cell-free DNA from...
...of human cardiomyocyte death using methylation patterns of circulating DNA.” Nature Communications (2018) Chris Lieu, Staff Writer Hebrew University of Jerusalem Refilin...
BioCentury | May 25, 2018
Preclinical News

Activating astrocytes to enhance memory

...In a paper published in Cell , researchers at The Hebrew University of Jerusalem showed that activating astrocytes in...
...neural network development and investigating whether astrocyte modulation could be translated into cognitive augmentation therapies. Sandi Wong Hebrew University of Jerusalem...
BioCentury | May 23, 2018
Distillery Techniques

Biomarkers

...Dor, Hebrew University of Jerusalem, Jerusalem, Israel email: yuvald@ekmd.huji.ac.il CONTACT: Giora Landesberg, same affiliation as above email: giora.lan@mail.huji.ac.il Chris Lieu Hebrew University of Jerusalem Refilin...
BioCentury | Dec 8, 2017
Company News

Therapix gains rights to synthetic cannabinoids from Hebrew University

...rights to IP for two synthetic cannabinoid compounds from Yissum Research Development Company Ltd., the Hebrew University of Jerusalem's...
...disorders. Hebrew University of Jerusalem, Jerusalem, Israel Therapix Biosciences Ltd. (Tel Aviv:TRPX; NASDAQ:TRPX), Tel Aviv, Israel Business: Neurology Jennie Walters Hebrew University of Jerusalem Therapix...
Items per page:
1 - 10 of 87